NxStage Medical, Inc. (NASDAQ:NXTM)‘s stock had its “hold” rating reaffirmed by Northland Securities in a research report issued on Wednesday, November 8th. They presently have a $30.00 price objective on the medical device company’s stock. Northland Securities’ price target indicates a potential upside of 15.83% from the stock’s current price.
Several other equities research analysts have also recently commented on the stock. Canaccord Genuity reissued a “hold” rating and set a $30.00 price target on shares of NxStage Medical in a research report on Tuesday, October 17th. BidaskClub cut shares of NxStage Medical from a “buy” rating to a “hold” rating in a research report on Thursday, July 13th. Zacks Investment Research lowered shares of NxStage Medical from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Leerink Swann lowered shares of NxStage Medical from an “outperform” rating to a “market perform” rating and boosted their price objective for the stock from $28.00 to $30.00 in a research note on Tuesday, August 22nd. Finally, Craig Hallum lowered shares of NxStage Medical from a “buy” rating to a “hold” rating in a research note on Monday, August 7th. Two research analysts have rated the stock with a sell rating and eight have given a hold rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $30.25.
Shares of NxStage Medical (NASDAQ:NXTM) traded down $0.09 during trading hours on Wednesday, reaching $25.90. 299,800 shares of the company’s stock traded hands, compared to its average volume of 820,591. NxStage Medical has a 52-week low of $20.45 and a 52-week high of $30.80.
COPYRIGHT VIOLATION WARNING: This article was first published by BBNS and is owned by of BBNS. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://baseballnewssource.com/markets/northland-securities-reiterates-hold-rating-for-nxstage-medical-inc-nxtm/1767721.html.
In other NxStage Medical news, President Joseph E. Turk, Jr. sold 1,000 shares of the stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $27.95, for a total transaction of $27,950.00. Following the transaction, the president now owns 73,903 shares in the company, valued at approximately $2,065,588.85. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Winifred L. Swan sold 3,500 shares of the stock in a transaction that occurred on Friday, October 20th. The stock was sold at an average price of $27.50, for a total transaction of $96,250.00. Following the transaction, the senior vice president now owns 15,270 shares in the company, valued at approximately $419,925. The disclosure for this sale can be found here. In the last quarter, insiders sold 13,300 shares of company stock worth $359,076. 4.70% of the stock is owned by company insiders.
Several institutional investors have recently modified their holdings of the company. FMR LLC lifted its holdings in shares of NxStage Medical by 31.8% during the 2nd quarter. FMR LLC now owns 9,860,278 shares of the medical device company’s stock worth $247,197,000 after acquiring an additional 2,378,077 shares during the period. Vanguard Group Inc. lifted its stake in NxStage Medical by 8.5% in the 1st quarter. Vanguard Group Inc. now owns 5,273,762 shares of the medical device company’s stock valued at $141,495,000 after purchasing an additional 412,233 shares during the last quarter. BlackRock Inc. lifted its stake in NxStage Medical by 38,360.4% in the 1st quarter. BlackRock Inc. now owns 4,413,326 shares of the medical device company’s stock valued at $118,408,000 after purchasing an additional 4,401,851 shares during the last quarter. Alpine Associates Management Inc. bought a new position in NxStage Medical in the 3rd quarter valued at approximately $110,163,000. Finally, Magnetar Financial LLC bought a new position in NxStage Medical in the 3rd quarter valued at approximately $84,927,000. 86.06% of the stock is owned by institutional investors.
NxStage Medical Company Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with our FREE daily email newsletter.